Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jul 1;43(6):685-693.
doi: 10.1097/MAO.0000000000003517.

Spironolactone Ameliorates Cochlear Implant Induced Endolymphatic Hydrops

Nathan J Creber  1 , Hayden T Eastwood  1 , Amy J Hampson  1 , Jonathon Lo  1 , Dongcheng Zhang  1 , Scott A Chambers  1 , Christo W Bester  1 , Peter R Thorne  2 , Stephen J O'Leary
Affiliations

Spironolactone Ameliorates Cochlear Implant Induced Endolymphatic Hydrops

Nathan J Creber et al. Otol Neurotol. .

Abstract

Background: Endolymphatic hydrops (EH) has been observed in both animal and human cochleae following cochlear implant (CI) surgery. We tested whether EH could be eliminated by administration of mineralocorticoid steroid antagonist spironolactone and explored the electrophysiological consequences of this.

Methods: Sixty-four adult guinea pigs underwent cochlear implantation with a dummy electrode. Animals then survived either 2, 7, or 28 days. Auditory function was monitored by recording electrocochleography from the round window membrane preimplantation, and on the last day of the experiment. Spironolactone or control solution was added to animals' feed for 7 days (if they survived that long) beginning immediately prior to surgery. The presence of EH was determined using thin-sheet laser imaging microscopy.

Results: Treatment with spironolactone resulted in significant reduction in EH in the second cochlear turn 7 days postimplantation. In all animals, the compound action potential (CAP) threshold was elevated 2 days postimplantation, but for most frequencies had recovered substantially by 28 days. There was no treatment effect on CAP thresholds. SP/AP ratios were elevated at day 2. The amplitude growth of the CAP did not differ between test and control groups at any time after implantation.

Conclusions: EH can be suppressed by antagonism of mineralocorticoid receptors in the week after cochlear implantation. Reduction in EH did not lead to any change in hearing, and there was no indication of synaptopathy signalled by reduced CAP amplitude at high sound intensities. We found no electrophysiological evidence that EH early after implantation impacts negatively upon preservation of residual hearing.

PubMed Disclaimer

Conflict of interest statement

The authors disclose no conflict of interest.

References

    1. Eshraghi AA. Prevention of cochlear implant electrode damage. Curr Opin Otolaryngol Head Neck Surg 2006;14:323–8.
    1. Chang A, Eastwood H, Sly D, James D, Richardson R, O’Leary S. Factors influencing the efficacy of round window dexamethasone protection of residual hearing post-cochlear implant surgery. Hear Res 2009;255:67–72.
    1. Connolly TM, Eastwood H, Kel G, Lisnichuk H, Richardson R, O’Leary S. Pre-operative intravenous dexamethasone prevents auditory threshold shift in a guinea pig model of cochlear implantation. Audiol Neurotol 2010;16:137–44.
    1. Maini S, Lisnichuk H, Eastwood H, et al. Targeted therapy of the inner ear. Audiol Neurotol 2009;14:402–10.
    1. Lee J, Ismail H, Lee JH, et al. Effect of both local and systemically administered dexamethasone on long-term hearing and tissue response in a Guinea pig model of cochlear implantation. Audiol Neuro-otol 2013;18:392–405.

Publication types